Clinical Trial Update: Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65) [Phase 1]

View source ↗

Summary

A Phase 1 study of oral QLT091001 in retinitis pigmentosa patients with an RPE65 mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• QLT091001 (retinoid)

Snippet

Sponsor: QLT Inc. | Conditions: Retinitis Pigmentosa (RP) | Phase 1 | Status: COMPLETED